# US 9,434,946 B2 · Combination therapy for treating hearing and balance disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,434,946 B2
- Document ID: US9434946B2
- Status: Granted
- Kind: B2
- Application number: 14/588,955
- Filed: 2015-01-04
- Published: 2015-05-07
- Granted: 2016-09-06
- Earliest claimed: 2012-01-12
- Assignees: Quark Pharmaceuticals, Inc.
- Applicants: Quark Pharmaceuticals, Inc.
- Inventors: Svetlana Adamsky; Elena Feinstein
- Web page: https://patentgrep.com/patent/US9434946B2

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61P 27/16: Otologicals
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2320/31: Combination therapy
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present application relates to combinations of inhibitors directed at down-regulation of genes associated with hearing loss including HES1, HES5, HEY2, CDKN1B and NOTCH1, exhibiting a beneficial effect and useful in treating or attenuating hearing loss, treating balance impairment, promoting the replacement, regeneration, or protection of otic (sensory) hair cells of the inner ear, and or effecting hearing restoration/regeneration.

## Claims

### Claim 1

A method of preventing, treating or delaying the progression of a hearing disorder, a hearing loss and/or a balance impairment in a subject, or preventing the loss of otic (sensory) hair cells of the inner ear in a subject comprising administering to the subject
(i) a combination of a HES1 (SEQ ID NO:1) inhibitor, a HES5 (SEQ ID NO:2) inhibitor and a HEY2 (SEQ ID NO:10) inhibitor; or
(ii) a combination of a CDKN1B (SEQ ID NO:7) inhibitor, a NOTCH1 (SEQ ID NO:11) inhibitor and a HEY2 (SEQ ID NO:10) inhibitor,
wherein the inhibitors are double stranded oligonucleotides.

### Claim 2 (depends on 1)

The method of claim 1, wherein the combination of inhibitors is administered to the subject in the same formulation.

### Claim 3 (depends on 1)

The method of claim 1, wherein the combination of inhibitors is administered to the subject in the different formulations.

### Claim 4 (depends on 1)

The method of claim 1, wherein the combination of inhibitors is administered to the subject by different routes.

### Claim 5 (depends on 1)

The method of claim 1, wherein one or more inhibitors is administered to the subject separately or sequentially.

### Claim 6 (depends on 1)

The method of claim 1, wherein one or more inhibitors is administered to the subject substantially simultaneously.

### Claim 7 (depends on 1)

The method of claim 1, wherein the inhibitors are co-administered to the subject by transtympanic injection or topically.

### Claim 8 (depends on 7)

The method of claim 7, wherein the topical administration comprises application of ear drops to the eardrum.

### Claim 9 (depends on 1)

The method of claim 1, wherein each of the double-stranded oligonucleotides comprises a strand configured to specifically bind mRNA encoding HES1, HES5, HEY2, CDKN1B or NOTCH1.

### Claim 10 (depends on 1)

The method of claim 1, wherein each of the double-stranded oligonucleotides comprises a dsRNA molecule having a sense strand and an antisense strand and the double-stranded oligonucleotides are linked or annealed in a RNAistar formation.

### Claim 11 (depends on 1)

The method of claim 1, wherein:
each double-stranded oligonucleotide comprises a sense strand and an antisense strand, wherein:
(a) each strand is independently 18 to 49 nucleotides in length;
(b) a 18 to 49 nucleotide sequence of the antisense strand is complementary to a sequence of an mRNA encoding (i) HES1, HES5 or HEY2 respectively, or (ii) CDKN1B, NOTCH1, or HEY2 respectively; and
(c) a 18 to 49 nucleotide sequence of the sense strand is complementary to the antisense strand.

### Claim 12 (depends on 1)

The method of claim 1, wherein at least one double-stranded oligonucleotide independently comprises a structure (A1):
(A1)
5′ (N)x - Z 3′
(antisense strand)
3′ Z′-(N′)y - z″ 5′
(sense strand)
wherein each of N and N′ is a ribonucleotide which may be unmodified or modified, or an unconventional moiety;
each of (N)x and (N′)y is an oligonucleotide in which each consecutive N or N′ is joined to the next N or N′ by a covalent bond;
each of Z and Z′ is independently present or absent, but if present is independently 1-5 consecutive nucleotides, 1-5 consecutive non-nucleotide moieties or a combination thereof covalently attached at the 3′ terminus of the strand in which it is present;
z″ may be present or absent, but if present is a capping moiety covalently attached at the 5′ terminus of (N′)y;
each of x and y is independently an integer between 18 and 40;
the sequence of (N′)y is complementary to the sequence of (N)x; and
(N)x comprises an antisense sequence complementary to an mRNA selected from (i) an mRNA encoding HES1, an mRNA encoding HES5, or an mRNA encoding HEY2, or (ii) an mRNA encoding CDKN1B, an mRNA encoding NOTCH1 or an mRNA encoding HEY2.

### Claim 13 (depends on 1)

The method of claim 1, wherein at least one double-stranded oligonucleotide independently comprises a structure (A2):
(A2)
5′ N1-(N)x - Z
3′ (antisense strand)
3′ Z′-N2-(N′)y-z″
5′ (sense strand)
wherein each of N2, N and N′ is independently an unmodified or modified ribonucleotide, or an unconventional moiety;
each of (N)x and (N′)y is an oligonucleotide in which each consecutive N or N′ is joined to the adjacent N or N′ by a covalent bond;
each of x and y is independently an integer between 17 and 39;
N2 is covalently bound to (N′)y;
N1 is covalently bound to (N)x and is mismatched to the target mRNA selected from HES1 mRNA, HES5 mRNA, HEY2 mRNA, CDKN1B mRNA and NOTCH1 mRNA or is a complementary deoxyribonucleotide moiety to the mRNA selected from HES1 mRNA, HES5 mRNA, HEY2 mRNA, CDKN1B mRNA and NOTCH1 mRNA;
N1 is a moiety selected from the group consisting of natural or modified: uridine, deoxyribouridine, ribothymidine, deoxyribothymidine, adenosine or deoxyadenosine, an abasic ribose moiety and an abasic deoxyribose moiety;
z″ may be present or absent, but if present is a capping moiety covalently attached at the 5′ terminus of N2-(N′)y; and
each of Z and Z′ is independently present or absent, but if present is independently 1-5 consecutive nucleotides, 1-5 consecutive non-nucleotide moieties or a combination thereof covalently attached at the 3′ terminus of the strand in which it is present;
the sequence of (N′)y has complementarity to the sequence of (N)x; and
the sequence of (N)x has complementarity to a consecutive sequence selected from a sequence in HES1 mRNA (SEQ ID NO:1), HES5 mRNA (SEQ ID NO:2), HEY2 mRNA (SEQ ID NO:10), CDKN1B mRNA (SEQ ID NO:7) and NOTCH1 mRNA (SEQ ID NO:11).

### Claim 14 (depends on 1)

The method of claim 1, wherein the combination being administered is (i).

### Claim 15 (depends on 1)

The method of claim 1, wherein the combination being administered is (ii).

### Claim 16 (depends on 1)

The method of claim 1, wherein the subject is human.

### Claim 17 (depends on 1)

The method of claim 1, wherein the inhibitors are administered in an amount and for a period of time sufficient to prevent, treat or delay the progression of the hearing disorder, the hearing loss and/or the balance impairment in the subject, or to prevent the loss of otic (sensory) hair cells of the inner ear in the subject.